

John R Teerlink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2168165/publications.pdf>

Version: 2024-02-01

175
papers

13,981
citations

25034

57
h-index

22832

112
g-index

191
all docs

191
docs citations

191
times ranked

11053
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. JAMA Cardiology, 2022, 7, 26.	6.1	59
2	Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 2022, 24, 365-374.	7.1	34
3	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
4	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	2.8	21
5	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009199.	3.9	3
6	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	30.7	341
7	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 2212-2220.	2.2	10
8	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
9	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
10	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. JAMA Cardiology, 2022, 7, 540.	6.1	20
11	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. Frontiers in Physiology, 2022, 13, 857538.	2.8	9
12	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 5006-5016.	2.2	15
13	Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 240-249.	7.1	17
14	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. Heart Failure Reviews, 2021, 26, 255-262.	3.9	0
15	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336.	1.6	222
16	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	27.0	381
17	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. JACC: Heart Failure, 2021, 9, 146-157.	4.1	17
18	Treatment of HF in an Era of Multiple Therapies. JACC: Heart Failure, 2021, 9, 1-12.	4.1	26

#	ARTICLE	IF	CITATIONS
19	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <sc>RELAX&AHF</sc> study. European Journal of Heart Failure, 2021, 23, 58-67.	7.1	10
20	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation: Heart Failure, 2021, 14, e007759.	3.9	3
21	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <sc>EMPULSE</sc> trial. European Journal of Heart Failure, 2021, 23, 826-834.	7.1	60
22	Haemodynamic effects of the nitroxyl donor cimlanod (<sc>BMS</sc> in chronic heart failure: a randomized trial. European Journal of Heart Failure, 2021, 23, 1147-1155.	7.1	13
23	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	7.1	630
24	The significance of left ventricular ejection time in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 541-551.	7.1	24
25	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. European Journal of Heart Failure, 2021, 23, 567-577.	7.1	26
26	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	1.7	362
27	Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circulation Research, 2021, 128, 1468-1486.	4.5	63
28	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 539-546.	3.0	22
29	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (<sc>COSMIC</sc> in <sc>HF</sc>). European Journal of Heart Failure, 2021, 23, 1052-1056.	7.1	10
30	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 2021, 78, 97-108.	2.8	73
31	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	1.7	7
32	Inotropic therapies in heart failure and cardiogenic shock: an educational review. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 676-686.	1.0	13
33	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195
34	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. Journal of the American Heart Association, 2021, 10, e022288.	3.7	8
35	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021, 240, 73-80.	2.7	1
36	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. JACC: Heart Failure, 2021, 9, 890-903.	4.1	7

#	ARTICLE	IF	CITATIONS
37	Drug Layering in Heart Failure. JACC: Heart Failure, 2021, 9, 775-783.	4.1	32
38	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. European Journal of Heart Failure, 2020, 22, 315-329.	7.1	24
39	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <sc>GALACTICâ€HF</sc> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
40	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	7.1	23
41	Cause of Death in Patients With Acute Heart Failure. JACC: Heart Failure, 2020, 8, 999-1008.	4.1	12
42	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	2.8	35
43	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	4.1	15
44	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e007814.	3.9	9
45	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e008007.	3.9	10
46	Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. ESC Heart Failure, 2020, 7, 3345-3354.	3.1	23
47	Challenges and Potential Improvements to Patient Access to Pharmaceuticals. Circulation, 2020, 142, 790-798.	1.6	7
48	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
49	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEMâ€HF, INOVATEâ€HF, and NECTARâ€HF. ESC Heart Failure, 2020, 7, 76-84.	3.1	41
50	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€HFâ€2 trial. European Journal of Heart Failure, 2020, 22, 726-738.	7.1	21
51	Systolic time intervals in patients with heart failure: time to teach new dogs old tricks. European Journal of Heart Failure, 2020, 22, 1183-1185.	7.1	5
52	Treatment with 24-hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. European Journal of Heart Failure, 2020, 22, 1684-1693.	7.1	48
53	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 329-340.	4.1	100
54	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50

#	ARTICLE	IF	CITATIONS
55	Endpoints in Heart Failure Drug Development. JACC: Heart Failure, 2020, 8, 429-440.	4.1	28
56	Mega-trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	7.1	11
57	Assessing the lifetime benefit of heart failure therapies. Lancet, The, 2020, 396, 75-77.	13.7	2
58	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. JACC: Heart Failure, 2019, 7, 913-921.	4.1	6
59	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	7.1	79
60	Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726.	27.0	174
61	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	7.1	155
62	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	1.7	16
63	Heart Failure Site-Based Research in the United States. JACC: Heart Failure, 2019, 7, 431-438.	4.1	6
64	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. ESC Heart Failure, 2019, 6, 1188-1198.	3.1	22
65	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	7.1	9
66	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031.	7.1	20
67	Cardiac Calcitropes, Myotropes, and Mitotropes. Journal of the American College of Cardiology, 2019, 73, 2345-2353.	2.8	93
68	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. ESC Heart Failure, 2019, 6, 297-307.	3.1	7
69	Impact of Autonomic Regulation Therapy in Patients with Heart Failure. Circulation: Heart Failure, 2019, 12, e005879.	3.9	50
70	Cognitive Decline Over Time in Patients With Systolic Heart Failure. JACC: Heart Failure, 2019, 7, 1042-1053.	4.1	26
71	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
72	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368

#	ARTICLE	IF	CITATIONS
73	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	2.8	211
74	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. JACC: Heart Failure, 2018, 6, 298-307.	4.1	4
75	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191.	1.7	157
76	What's Next for Acute Heart Failure Research?. Academic Emergency Medicine, 2018, 25, 85-93.	1.8	11
77	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clinical Research in Cardiology, 2018, 107, 170-181.	3.3	27
78	Systolic blood pressure reduction during the first 24h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322.	7.1	20
79	the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial. Journal of Cardiac Failure, 2018, 24, 812.	1.7	5
80	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation, 2018, 138, 1039-1053.	1.6	24
81	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. Clinical Cardiology, 2018, 41, 945-952.	1.8	22
82	Patient-Reported Outcome Instruments in Heart Failure. JACC: Heart Failure, 2018, 6, 561-563.	4.1	2
83	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ESC Heart Failure, 2018, 5, 800-808.	3.1	25
84	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). American Journal of Cardiology, 2018, 122, 821-827.	1.6	3
85	Cardioprotective cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal, 2017, 38, ehw543.	2.2	148
86	Agents with vasodilator properties in acute heart failure. European Heart Journal, 2017, 38, 317-325.	2.2	50
87	The safety of sacubitril-valsartan for the treatment of chronic heart failure. Expert Opinion on Drug Safety, 2017, 16, 257-263.	2.4	8
88	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	11
89	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure, 2017, 19, 739-747.	7.1	28
90	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	2.9	74

#	ARTICLE	IF	CITATIONS
91	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	7.1	34
92	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	7.1	104
93	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	2.2	102
94	Heart failure. <i>Lancet</i> , The, 2017, 390, 1981-1995.	13.7	483
95	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	4.1	78
96	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	2.8	69
97	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	2.7	10
98	Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , 2017, 19, 1520-1529.	7.1	89
99	Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 465-490.	1.8	23
100	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
101	Mind the Gap: Current Challenges and Future State of Heart Failure Care. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1434-1449.	1.7	19
102	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 603-610.	4.1	2
103	Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. <i>Journal of Cardiac Failure</i> , 2017, 23, 63-71.	1.7	17
104	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016, 23, 922-931.	1.8	10
105	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. <i>Stroke</i> , 2016, 47, 2031-2037.	2.0	44
106	Patient-Reported Outcomes in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 791-804.	4.1	41
107	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	7.1	45
108	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	7.1	70

#	ARTICLE	IF	CITATIONS
109	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.	13.7	229
110	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	4.1	49
111	Patient and Facility Variation in Costs of VA Heart Failure Patients. <i>JACC: Heart Failure</i> , 2016, 4, 551-558.	4.1	21
112	Ivabradine. <i>Circulation</i> , 2016, 133, 2066-2075.	1.6	40
113	Lung ultrasound: a B-line™ to the prediction of decompensated heart failure. <i>European Heart Journal</i> , 2016, 37, 1252-1254.	2.2	19
114	Serelaxin in the Treatment of Acute Heart Failure. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 213-218.	1.5	0
115	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	15
116	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	1.7	53
117	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	1.7	11
118	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	80
119	CHA ₂ DS ₂ -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. <i>European Journal of Heart Failure</i> , 2016, 18, 1261-1266.	7.1	25
120	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	7.1	49
121	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2016, 22, 618-627.	1.7	4
122	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <small>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</small>	1.8	26
123	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	35
124	Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 117-127.	4.1	37
125	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	1.7	34
126	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	2.8	191

#	ARTICLE	IF	CITATIONS
127	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	3.3	16
128	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016, 22, 815-822.	1.7	27
129	Serelaxin and acute heart failure. <i>Heart</i> , 2016, 102, 95-99.	2.9	22
130	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	1.7	35
131	Cardiac myosin activators: up and coming. <i>European Journal of Heart Failure</i> , 2015, 17, 750-752.	7.1	1
132	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.1	60
133	Screening for Sleep-Disordered Breathing in Patients Hospitalized for Heart Failure —. <i>JACC: Heart Failure</i> , 2015, 3, 732-733.	4.1	8
134	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
135	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015, 21, 179-188.	1.7	65
136	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	7.1	48
137	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	4.1	68
138	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	1.6	7
139	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	3.9	21
140	Team-based Care for Patients Hospitalized with Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 359-370.	2.1	9
141	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	4.1	44
142	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2015, 21, 27-43.	1.7	73
143	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. <i>Circulation</i> , 2015, 132, .	1.6	0
144	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>PLoS ONE</i> , 2014, 9, e113447.	2.5	15

#	ARTICLE	IF	CITATIONS
145	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	3.9	107
146	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <sc>VERITAS</sc> study. <i>European Journal of Heart Failure</i> , 2014, 16, 1362-1371.	7.1	28
147	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	2.2	276
148	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	1.7	38
149	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the <sc>PROTECT</sc> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	7.1	71
150	Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 103-111.	4.1	337
151	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	2.8	159
152	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	2.8	397
153	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2013, 381, 29-39.	13.7	810
154	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	3.9	103
155	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	7.1	115
156	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	2.7	60
157	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	27.0	511
158	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. <i>Lancet</i> , The, 2011, 378, 676-683.	13.7	295
159	Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. <i>Lancet</i> , The, 2011, 378, 667-675.	13.7	226
160	Mind or Body. <i>Archives of Internal Medicine</i> , 2011, 171, 758-9.	3.8	0
161	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. <i>Cardiology</i> , 2011, 119, 96-105.	1.4	56
162	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	7.1	88

#	ARTICLE	IF	CITATIONS
163	Ivabradine in heart failure—no paradigm SHIFT yet. <i>Lancet, The</i> , 2010, 376, 847-849.	13.7	45
164	Rolofylline, an Adenosine A ₁ Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	27.0	473
165	Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. <i>Heart Failure Reviews</i> , 2009, 14, 243-253.	3.9	85
166	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet, The</i> , 2009, 373, 1429-1439.	13.7	387
167	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2009.	7.4	330
168	Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2245-2252.	2.8	175
169	Overview of Randomized Clinical Trials in Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 59-67.	1.6	50
170	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , 2005, 150, 46-53.	2.7	67
171	Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION. <i>Journal of Cardiac Failure</i> , 2003, 9, 158-163.	1.7	13
172	Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. <i>American Heart Journal</i> , 2003, 145, S26-S33.	2.7	69
173	Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): Approaching the asymptote of efficacy?. <i>Journal of Cardiac Failure</i> , 2002, 8, 124-127.	1.7	68
174	Reversal of left ventricular remodeling: Role of the endothelin pathway. <i>Journal of Cardiac Failure</i> , 2002, 8, S494-S499.	1.7	11
175	The role of endothelin in the pathogenesis of heart failure. <i>Current Cardiology Reports</i> , 2002, 4, 206-212.	2.9	14